Biosimilars offer major cost savings over brand-name biologics, but insurance coverage rules like prior authorization and same-tier placement often block patients from accessing them. Here’s how coverage works-and what’s changing in 2026.
Read more
Insurers push providers to use generic drugs to cut costs, but rigid substitution rules are causing delays, patient harm, and administrative overload. Learn how providers are adapting-and where the system is failing.
Read more